Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ATI-2231

Small molecule · Inhibitor of MAPKAPK2

Phase 1 Most advanced trial (none active)
1 Registered trials

What is ATI-2231?

ATI-2231 is an orally bioavailable inhibitor of MAPKAPK2 (MK2) that targets the p38MAPK-MK2 complex. By inhibiting p38MAPK phosphorylation and MK2 activation, it abrogates DNA repair, leading to DNA damage accumulation and apoptosis. It is studied in advanced solid tumors, with potential to potentiate DNA-damaging agent cytotoxicity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
MAPKAPK2, p38MAPK (MAPK14) (secondary target)
Mechanism
Inhibitor of MAPKAPK2
Pathways
p38MAPK/MK2 signaling, DNA repair, apoptosis
Therapy area
Oncology
In trials of
ACRS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05791474 Phase 1 Advanced Solid Tumor Withdrawn ACRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorAdvanced Solid Tumor Malignancies

Other drugs acting on MAPKAPK2

Zunsemetinib Phase 2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.